Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals

First-in-Human Application of Terbium-161: A Feasibility Study Using 161Tb-DOTATOC

(2021) Richard P. Baum et al.   JOURNAL OF NUCLEAR MEDICINE

Preliminary Study of a 1,5-Benzodiazepine-Derivative Labelled with Indium-111 for CCK-2 Receptor Targeting

(2021) Marco Verona et al.   MOLECULES

The importance of the RET gene in thyroid cancer and therapeutic implications

(2021) Domenico Salvatore et al.   Nature Reviews Endocrinology

Diagnostic accuracy of routine calcitonin measurement for detection of medullary thyroid carcinoma in the management of patients with nodular thyroid disease: a meta-analysis

(2021) Irfan Vardarli et al.   Endocrine Connections

A New Turn in Peptide-Based Imaging Agents: Foldamers Afford Improved Theranostics Targeting Cholecystokinin-2 Receptor-Positive Cancer

(2021) Alicia Corlett et al.   JOURNAL OF MEDICINAL CHEMISTRY

Improved Tumor-Targeting with Peptidomimetic Analogs of Minigastrin 177Lu-PP-F11N

(2021) Nathalie M. Grob et al.   Cancers

Radiopharmaceutical Formulation and Preclinical Testing of 68Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial

(2021) Anton A. Hörmann et al.   Pharmaceuticals

Comparison of 5 Different PET Radiopharmaceuticals for the Detection of Recurrent Medullary Thyroid Carcinoma

(2020) Sang-Woo Lee et al.   CLINICAL NUCLEAR MEDICINE

CCK2R antagonists: from SAR to clinical trials

(2020) Doroteja Novak et al.   DRUG DISCOVERY TODAY

Highlights of the 32th Annual Congress of the EANM, Barcelona 2019: the nucleolympic games of nuclear medicine—a global competition for excellence

(2020) Sarah M. Schwarzenböck et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Design of Radiolabeled Analogs of Minigastrin by Multiple Amide-to-Triazole Substitutions

(2020) Nathalie M. Grob et al.   JOURNAL OF MEDICINAL CHEMISTRY

Triazolo-Peptidomimetics: Novel Radiolabeled Minigastrin Analogs for Improved Tumor Targeting

(2020) Nathalie M. Grob et al.   JOURNAL OF MEDICINAL CHEMISTRY

Radiolabelled CCK 2 R Antagonists Containing PEG Linkers: Design, Synthesis and Evaluation

(2020) Doroteja Novak et al.   ChemMedChem

Cholecystokinin-2 receptor targeting with radiolabeled peptides: current status and future directions.

(2020) Maximilian Klingler et al.   CURRENT MEDICINAL CHEMISTRY

Comparison of PET/CT imaging with [18F]FDOPA and cholecystokinin-2 receptor targeting [68Ga]Ga-DOTA-MGS5 in a patient with advanced medullary thyroid carcinoma

(2020) Christian Uprimny et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

[99mTc]Tc-DGA1, a Promising CCK2R-Antagonist-Based Tracer for Tumor Diagnosis with Single-Photon Emission Computed Tomography

(2020) Aikaterini Kaloudi et al.   MOLECULAR PHARMACEUTICS

Initial In Vitro and In Vivo Evaluation of a Novel CCK2R Targeting Peptide Analog Labeled with Lutetium-177

(2020) Anton Amadeus Hörmann et al.   MOLECULES

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers

(2020) Lori J. Wirth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Stabilization Strategies for Linear Minigastrin Analogues: Further Improvements via the Inclusion of Proline into the Peptide Sequence

(2020) Maximilian Klingler et al.   JOURNAL OF MEDICINAL CHEMISTRY

Elucidating the Structure–Activity Relationship of the Pentaglutamic Acid Sequence of Minigastrin with Cholecystokinin Receptor Subtype 2

(2019) Andreas Ritler et al.   BIOCONJUGATE CHEMISTRY

Survival and long-term biochemical cure in medullary thyroid carcinoma in Denmark 1997-2014: A nationwide study

(2019) Jes Sloth Mathiesen et al.   THYROID

Therapeutic Radiometals: Worldwide Scientific Literature Trend Analysis (2008–2018)

(2019) Licia Uccelli et al.   MOLECULES

Radiometals for imaging and theranostics, current production and future perspectives

(2019) Renata Mikolajczak et al.   JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS

EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma

(2019) Luca Giovanella et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Cholecystokinin-2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma - Results of the Lumed Phase 0a Study

(2019) Christof Rottenburger et al.   JOURNAL OF NUCLEAR MEDICINE

Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations

(2019) Rossella Elisei et al.   Genes

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2019) S Filetti et al.   ANNALS OF ONCOLOGY

Clinical utility of 177 Lu‐DOTATATE PRRT in somatostatin receptor‐positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity

(2019) Rahul V. Parghane et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Targeting of the cholecystokinin-2 receptor with the minigastrin analog177Lu-DOTA-PP-F11N: does the use of protease inhibitors further improve in vivo distribution?

(2018) Alexander Walter Sauter et al.   JOURNAL OF NUCLEAR MEDICINE

Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting

(2018) Maximilian Klingler et al.   Theranostics

Promising Scandium Radionuclides for Nuclear Medicine: A Review on the Production and Chemistry up to In Vivo Proofs of Concept

(2018) Sandrine Huclier-Markai et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Multimerization results in formation of re-bindable metabolites: A proof of concept study with FSC-based minigastrin imaging probes targeting CCK2R expression

(2018) Dominik Summer et al.   PLoS One

DOTA-MGS5, a new cholecystokinin-2 receptor targeting peptide analog with optimized targeting profile for theranostic use

(2018) Maximilian Klingler et al.   JOURNAL OF NUCLEAR MEDICINE

Somatostatin Receptor Antagonists for Imaging and Therapy

(2017) Melpomeni Fani et al.   JOURNAL OF NUCLEAR MEDICINE

Improving theIn VivoProfile of Minigastrin Radiotracers: A Comparative Study Involving the Neutral Endopeptidase Inhibitor Phosphoramidon

(2016) Aikaterini Kaloudi et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Rak rdzeniasty tarczycy — badanie PET/CT ze znakowanymi 68Ga analogami gastryny i somatostatyny

(2016) Jolanta Kunikowska et al.   Endokrynologia Polska

The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the “evidence-based” refusal to endorse them by EANM due to the “not evidence-based” marginalization of the role of Nuclear Medicine

(2016) Giorgio Treglia et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [111In-DOTA]MG11—first estimates for clinical translation

(2016) Aikaterini Kaloudi et al.   EJNMMI Research

Stereochemistry of Amino Acid Spacers Determines the Pharmacokinetics of 111In–DOTA–Minigastrin Analogues for Targeting the CCK2/Gastrin Receptor

(2015) Petra Kolenc Peitl et al.   BIOCONJUGATE CHEMISTRY

Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma

(2015) Samuel A. Wells et al.   THYROID

Evaluation of a Nonpeptidic Ligand for Imaging of Cholecystokinin 2 Receptor-Expressing Cancers

(2014) C. Wayua et al.   JOURNAL OF NUCLEAR MEDICINE

PET and SPECT Imaging of a Radiolabeled Minigastrin Analogue Conjugated with DOTA, NOTA, and NODAGA and Labeled with 64Cu, 68Ga, and 111In

(2014) S. Roosenburg et al.   MOLECULAR PHARMACEUTICS

"To Serve and Protect": Enzyme Inhibitors as Radiopeptide Escorts Promote Tumor Targeting

(2013) B. A. Nock et al.   JOURNAL OF NUCLEAR MEDICINE

Future prospects for SPECT imaging using the radiolanthanide terbium-155 — production and preclinical evaluation in tumor-bearing mice

(2013) Cristina Müller et al.   NUCLEAR MEDICINE AND BIOLOGY

Radiopharmaceutical development of radiolabelled peptides

(2012) Melpomeni Fani et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement

(2012) P.-Y. Salaun et al.   JOURNAL OF NUCLEAR MEDICINE

Comparison of the binding and internalization properties of 12 DOTA-coupled and 111In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607

(2011) Luigi Aloj et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Comparative biodistribution of 12 111In-labelled gastrin/CCK2 receptor-targeting peptides

(2011) Peter Laverman et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607

(2011) Meltem Ocak et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Highly Improved Metabolic Stability and Pharmacokinetics of Indium-111-DOTA-Gastrin Conjugates for Targeting of the Gastrin Receptor

(2011) Petra Kolenc-Peitl et al.   JOURNAL OF MEDICINAL CHEMISTRY

Bombesin Antagonist-Based Radioligands for Translational Nuclear Imaging of Gastrin-Releasing Peptide Receptor-Positive Tumors

(2011) K. Abiraj et al.   JOURNAL OF NUCLEAR MEDICINE

Evaluation of a 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid-Conjugated Bombesin-Based Radioantagonist for the Labeling with Single-Photon Emission Computed Tomography, Positron Emission Tomography, and Therapeutic Radionuclides

(2009) R. Mansi et al.   CLINICAL CANCER RESEARCH

Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma

(2009) Alida C. Fröberg et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Cyclic Minigastrin Analogues for Gastrin Receptor Scintigraphy with Technetium-99m: Preclinical Evaluation

(2009) Elisabeth von Guggenberg et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeting of CCK-2 Receptor-Expressing Tumors Using a Radiolabeled Divalent Gastrin Peptide

(2009) J. K. Sosabowski et al.   JOURNAL OF NUCLEAR MEDICINE

Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours

(2008) Stephan Good et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Bombesin Receptor Antagonists May Be Preferable to Agonists for Tumor Targeting

(2008) R. Cescato et al.   JOURNAL OF NUCLEAR MEDICINE

Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides

(2008) Wouter A.P. Breeman et al.   NUCLEAR MEDICINE AND BIOLOGY